These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37312163)

  • 1. Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    O'Leary KA; Bates AM; Jin WJ; Burkel BM; Sriramaneni RN; Emma SE; Nystuen EJ; Sumiec EG; Ponik SM; Morris ZS; Schuler LA
    Breast Cancer Res; 2023 Jun; 25(1):68. PubMed ID: 37312163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
    Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment.
    Benslimane Y; Amalfi K; Lapin S; Perrino S; Brodt P
    Cancer Res Commun; 2024 Aug; 4(8):1963-1977. PubMed ID: 39007345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
    Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
    Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
    Wolfson B; Padget MR; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
    Abrahamsson A; Rodriguez GV; Dabrosin C
    Cancer Res; 2020 Oct; 80(20):4487-4499. PubMed ID: 32855207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells.
    Wang J; Yang Q; Haffty BG; Li X; Moran MS
    Biochem Biophys Res Commun; 2013 Feb; 431(2):146-51. PubMed ID: 23313506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    Chakraborty B; Byemerwa J; Shepherd J; Haines CN; Baldi R; Gong W; Liu W; Mukherjee D; Artham S; Lim F; Bae Y; Brueckner O; Tavares K; Wardell SE; Hanks BA; Perou CM; Chang CY; McDonnell DP
    J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34637400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of estrogen receptor signaling in suppressing the immune response to cancer.
    Rae JM; Lippman ME
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ERβ/HER Oncogenic Network in
    Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
    Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness.
    Larsen SS; Madsen MW; Jensen BL; Lykkesfeldt AE
    Int J Cancer; 1997 Sep; 72(6):1129-36. PubMed ID: 9378550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.